Potential of lectins and their recognizable glycoconjugates in tumor study and therapy technologies

The analysis of the communication role of lectin and glycan receptors in the recognition and binding of patterns in human antitumor immunity is carried out. Anticancer current technologies involved lectins and their recognized glycoconjugates are systematized. Examples include realization of molecular, assembly, and intercellular connections based on lectin-glycan interactions in the study of the most known malignant tumors, including tumor cell lines. The most significant antitumor strategies for the combined use of lectins and glycans in relation to the functioning of the basic communication network of the body are indicated. Modulation of the expression of various lectins and their interactions with glycoconjugate patterns, as well as regulation of key combinations of lectins and CD antigens (including effector pairs in communication axes) between populations of protective cells (dendritic cells cDC, mDC, MoDC, pDC; macrophages M2 and M1, mucosal M cells, NK and CAT-T cells, CTL, other CD-antigen labeled types) have a place in the communication network. Such cell populations are involved in enhancing the responses of innate (basic) and related adaptive (superstructure) immunity. The effects of lectins and glycoconjugates are due to the targeted recognition of receptor glycoconjugates or lectin patterns by innate immune cells and the initiation of further intercellular and intracellular communication cascades. Receptor and soluble lectins and glycoconjugates act as organized and directed synergists and/or antagonists. The most commonly used receptor lectins, their ligands and other communication axes effectors will be useful in the development of anticancer procedures, strategies, and vaccines. In general, lectins and their recognizable glycoconjugates have significant potential for combination therapy of tumors.